JLT warns pharma firms of non-damage risks
Broker JLT claims regulatory fears, intellectual property risks and counterfeiting are driving demand for its EPIC non-damage business interruption product developed for the life science and pharmaceuticals market
James Bird, partner, JLT’s specialist life science team, says: "We have found that the growing demand for our EPIC product is due in the main to three key risks: regulatory, intellectual property and
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe
You are currently unable to print this content. Please contact info@postonline.co.uk to find out more.
You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Most read
- RSA ‘pragmatic’ on product review as NIG acquisition completes
- Direct Line Group confirms Milliner amid raft of leadership hires
- Wakam looking to exploit ‘unlimited UK potential’ following regulator approval